Troubled Space Scientists Ask NASA: What Price Freedom?

The $30 billion space station planned by the National Aeronautics and Space Administration is likely to be the biggest United States science project of the next two decades--employing the most scientists and engineers, drawing the most federal science funds, and commanding the most public attention of any government-supported research. Yet a growing consensus among U.S. scientists, several of whom have recently testified before Congress, is that the space station Freedom will not yield signifi

Written byKen Kalfus
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Yet a growing consensus among U.S. scientists, several of whom have recently testified before Congress, is that the space station Freedom will not yield significant benefits for science; that it, in fact, has no scientific rationale at all.

In the course of the space station's design and recent redesign, a number of its planned laboratories have been either removed or scaled back. It has lost a number of external science experiments, including a space telescope and instruments for observing Earth. Also removed was a large superconducting magnet, which was to represent a major step forward for cosmic ray research. The microgravity laboratory is also gone. Many scientists, being urged by NASA to support the redesigned space station, anyway, are now wondering whether Freedom is just another word for nothing left to lose.

The U.S. is on the verge of making a decision on whether to go ahead with the space ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies